Does the media prefer AVLN or GRFS?

In the previous week, Avalyn Pharma had 2 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Avalyn Pharma and 1 mentions for Grifols. Avalyn Pharma's average media sentiment score of 0.64 beat Grifols' score of 0.00 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, AVLN or VKTX?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$21.83 N/A Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A

Is AVLN or VKTX more profitable?

Avalyn Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Viking Therapeutics N/A -71.31% -65.35%

Does the media favor AVLN or VKTX?

In the previous week, Viking Therapeutics had 7 more articles in the media than Avalyn Pharma. MarketBeat recorded 10 mentions for Viking Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.64 beat Viking Therapeutics' score of 0.28 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVLN or ACAD?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 3 mentions for Avalyn Pharma. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Avalyn Pharma's score of 0.64 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVLN or TNGX more profitable?

Avalyn Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Tango Therapeutics N/A -41.54% -33.44%

Does the media refer more to AVLN or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.64 beat Tango Therapeutics' score of 0.35 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVLN or DNLI more profitable?

Avalyn Pharma's return on equity of 0.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Denali Therapeutics N/A -52.20% -43.86%

Does the media prefer AVLN or DNLI?

In the previous week, Avalyn Pharma and Avalyn Pharma both had 3 articles in the media. Denali Therapeutics' average media sentiment score of 0.93 beat Avalyn Pharma's score of 0.64 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avalyn Pharma (AVLN) Competitors

$28.63 +0.33 (+1.17%)

As of 04:00 PM Eastern

Compare

AVLN vs. GRFS, VKTX, ACAD, TNGX, and DNLI

Should you buy Avalyn Pharma stock or one of its competitors? MarketBeat compares Avalyn Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalyn Pharma include Grifols (GRFS), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Tango Therapeutics (TNGX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Avalyn Pharma compare to Grifols?

Avalyn Pharma (NASDAQ:AVLN) and Grifols (NASDAQ:GRFS) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 106.08%. Grifols has a consensus price target of $10.00, indicating a potential upside of 31.41%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Grifols has a net margin of 5.54% compared to Avalyn Pharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Grifols	5.54%	6.21%	2.39%

In the previous week, Avalyn Pharma had 2 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Avalyn Pharma and 1 mentions for Grifols. Avalyn Pharma's average media sentiment score of 0.64 beat Grifols' score of 0.00 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.05

Summary

Avalyn Pharma and Grifols tied by winning 6 of the 12 factors compared between the two stocks.

How does Avalyn Pharma compare to Viking Therapeutics?

Avalyn Pharma (NASDAQ:AVLN) and Viking Therapeutics (NASDAQ:VKTX) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Avalyn Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Viking Therapeutics	N/A	-71.31%	-65.35%

In the previous week, Viking Therapeutics had 7 more articles in the media than Avalyn Pharma. MarketBeat recorded 10 mentions for Viking Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.64 beat Viking Therapeutics' score of 0.28 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 106.08%. Viking Therapeutics has a consensus price target of $93.60, indicating a potential upside of 157.28%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

Viking Therapeutics beats Avalyn Pharma on 6 of the 11 factors compared between the two stocks.

How does Avalyn Pharma compare to ACADIA Pharmaceuticals?

Avalyn Pharma (NASDAQ:AVLN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Avalyn Pharma currently has a consensus target price of $59.00, suggesting a potential upside of 106.08%. ACADIA Pharmaceuticals has a consensus target price of $32.94, suggesting a potential upside of 31.29%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Avalyn Pharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Avalyn Pharma's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

ACADIA Pharmaceuticals has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 3 mentions for Avalyn Pharma. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Avalyn Pharma's score of 0.64 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Avalyn Pharma on 11 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Tango Therapeutics?

Avalyn Pharma (NASDAQ:AVLN) and Tango Therapeutics (NASDAQ:TNGX) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Avalyn Pharma has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Tango Therapeutics	$62.38M	63.86	-$101.59M	-$0.83	N/A

Avalyn Pharma presently has a consensus price target of $59.00, suggesting a potential upside of 106.08%. Tango Therapeutics has a consensus price target of $42.15, suggesting a potential upside of 53.06%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Avalyn Pharma is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avalyn Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Tango Therapeutics	N/A	-41.54%	-33.44%

In the previous week, Tango Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.64 beat Tango Therapeutics' score of 0.35 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalyn Pharma beats Tango Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Avalyn Pharma compare to Denali Therapeutics?

Avalyn Pharma (NASDAQ:AVLN) and Denali Therapeutics (NASDAQ:DNLI) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Avalyn Pharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Denali Therapeutics	N/A	-52.20%	-43.86%

In the previous week, Avalyn Pharma and Avalyn Pharma both had 3 articles in the media. Denali Therapeutics' average media sentiment score of 0.93 beat Avalyn Pharma's score of 0.64 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Denali Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 106.08%. Denali Therapeutics has a consensus price target of $35.08, indicating a potential upside of 53.20%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Avalyn Pharma is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Avalyn Pharma has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Denali Therapeutics	$330.53M	11.00	-$512.54M	-$2.88	N/A

Summary

Avalyn Pharma and Denali Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Avalyn Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVLN vs. The Competition

Export

Metric	Avalyn Pharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.25B	$789.95M	$4.39B	$12.28B
Dividend Yield	N/A	4.84%	38.14%	9.39%
P/E Ratio	-1.31	1.50	23.54	23.94
Price / Sales	N/A	111.87	135.69	91.95
Price / Cash	N/A	22.05	30.17	47.25
Price / Book	N/A	8.67	12.25	6.14
Net Income	N/A	-$3.14M	$120.21M	$331.74M
7 Day Performance	2.84%	-4.23%	-1.78%	-1.72%
1 Month Performance	-8.97%	0.74%	-2.11%	-1.44%
1 Year Performance	N/A	30.33%	10.69%	16.97%

Avalyn Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVLN Avalyn Pharma	4.1076 of 5 stars	$28.63 +1.2%	$59.00 +106.1%	N/A	$1.25B	N/A	N/A	51
GRFS Grifols	4.0144 of 5 stars	$7.27 -0.3%	$10.00 +37.6%	-26.9%	$4.96B	$8.51B	38.26	25,247	Positive News Upcoming Earnings
VKTX Viking Therapeutics	3.0987 of 5 stars	$38.86 -5.5%	$93.60 +140.9%	+15.8%	$4.78B	N/A	N/A	20	Analyst Forecast
ACAD ACADIA Pharmaceuticals	4.7902 of 5 stars	$26.22 -0.7%	$32.94 +25.6%	+13.5%	$4.52B	$1.07B	11.92	510
TNGX Tango Therapeutics	2.5245 of 5 stars	$31.06 +1.8%	$41.50 +33.6%	+321.9%	$4.41B	$62.38M	N/A	90	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVLN) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalyn Pharma (AVLN) Competitors

AVLN vs. GRFS, VKTX, ACAD, TNGX, and DNLI

How does Avalyn Pharma compare to Grifols?

Summary

How does Avalyn Pharma compare to Viking Therapeutics?

Summary

How does Avalyn Pharma compare to ACADIA Pharmaceuticals?

Summary

How does Avalyn Pharma compare to Tango Therapeutics?

Summary

How does Avalyn Pharma compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalyn Pharma (AVLN) Competitors

AVLN vs. GRFS, VKTX, ACAD, TNGX, and DNLI

How does Avalyn Pharma compare to Grifols?

Do analysts prefer AVLN or GRFS?

Is AVLN or GRFS more profitable?

Does the media prefer AVLN or GRFS?

Which has better valuation and earnings, AVLN or GRFS?

Summary

How does Avalyn Pharma compare to Viking Therapeutics?

Is AVLN or VKTX more profitable?

Does the media favor AVLN or VKTX?

Which has preferable valuation and earnings, AVLN or VKTX?

Do institutionals & insiders believe in AVLN or VKTX?

Do analysts recommend AVLN or VKTX?

Summary

How does Avalyn Pharma compare to ACADIA Pharmaceuticals?

Do institutionals & insiders hold more shares of AVLN or ACAD?

Do analysts recommend AVLN or ACAD?

Is AVLN or ACAD more profitable?

Which has preferable valuation & earnings, AVLN or ACAD?

Does the media prefer AVLN or ACAD?

Summary

How does Avalyn Pharma compare to Tango Therapeutics?

Which has stronger earnings & valuation, AVLN or TNGX?

Do analysts rate AVLN or TNGX?

Do institutionals and insiders hold more shares of AVLN or TNGX?

Is AVLN or TNGX more profitable?

Does the media refer more to AVLN or TNGX?

Summary

How does Avalyn Pharma compare to Denali Therapeutics?

Is AVLN or DNLI more profitable?

Does the media prefer AVLN or DNLI?

Do institutionals & insiders believe in AVLN or DNLI?

Do analysts rate AVLN or DNLI?

Which has better earnings & valuation, AVLN or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools